potenti
effect
fucos
mannos
ligand
fml
vaccin
immunotherapi
canin
viscer
leishmaniasi
assay
five
mongrel
dog
experiment
infect
leishmania
donovani
leishmania
chagasi
natur
infect
dog
seroposit
fml
complet
asymptomat
clinic
sign
experiment
infect
symptomat
dog
disappear
complet
vaccin
protect
obtain
anim
remain
asymptomat
idr
posit
parasit
free
year
infect
furthermor
asymptomat
fmlvaccin
treat
dog
show
stabl
antifml
level
increas
level
posit
dth
respons
whole
experi
twentytwo
month
complet
vaccin
obit
due
viscer
leishmaniasi
record
dog
still
asymptomat
healthi
parasit
free
hand
dog
kalaazar
obit
record
control
group
receiv
treatment
period
fmlseroposit
asymtpomat
begin
assay
result
indic
fmlvaccin
effect
immunotherapi
viscer
leishmaniasi
asymptomat
infect
dog
normal
proport
lymphocyt
detect
pbmc
fac
analysi
dog
submit
immunotherapi
suggest
noninfecti
condit
anim
show
well
significantli
increas
percent
lymphocyt
expect
quillaja
saponin
quila
vaccin
treatment
human
viscer
leishmaniasi
kalaazar
sever
frequent
lethal
parasit
diseas
spread
world
new
human
kalaazar
case
regist
annual
india
sudan
bangladesh
brazil
diseas
canid
zoonosi
etiolog
agent
leishmania
chagasi
leishmania
infantum
expos
skin
fox
wild
canid
dog
transmit
human
sandfli
byte
zoonot
viscer
leishmaniasi
zvl
reemerg
canid
zoonos
epidemiolog
control
involv
elimin
seroposit
infect
dog
insecticid
treatment
within
domest
peridomest
habit
systemat
treatment
human
case
kill
seroposit
dog
wide
practic
brazil
china
unaccept
europ
canin
surveil
program
labori
expens
requir
continu
vigil
sensit
serolog
diagnost
method
effect
furthermor
sinc
mani
seroposit
infect
dog
asymptomat
owner
complianc
complic
even
though
infect
asymptomat
dog
sandfli
alreadi
prove
sacrific
seroposit
anim
epidemiolog
control
still
perform
chemotherapi
infect
dog
use
pentaval
antimoni
mostli
unsuccess
even
caus
exacerb
diseas
report
increas
surviv
rate
possibl
cure
potenti
howev
stimul
dog
therapi
zvl
treatment
infect
dog
becam
usual
europ
late
brazil
howev
still
recommend
sinc
human
canin
treatment
perform
drug
fact
give
rise
drugresist
parasit
mani
relaps
describ
treatment
clinic
major
sign
diseas
disappear
although
might
indic
complet
absenc
parasit
inde
dog
shown
infect
sandfli
sever
month
posttreat
presenc
latent
infect
dog
typic
import
maintain
longterm
presenc
parasit
endem
region
develop
protect
vaccin
canin
viscer
leishmaniasi
recommend
possibl
tool
effect
erad
diseas
reduc
offer
parasit
sandfli
vector
consequ
number
human
kalaazar
case
howev
effect
vaccin
human
kalaazar
yet
avail
report
literatur
deal
vaccin
canin
viscer
leishmaniasi
dunan
et
al
use
l
infantum
semipurifi
lyophil
protein
prepar
kd
paradox
achiev
significantli
higher
rate
infect
vaccin
control
dog
first
year
experi
vaccin
effect
murin
model
develop
protect
canin
kalaazar
field
mayrink
et
al
use
l
braziliensi
lysat
bcg
vaccin
formul
relat
leishvacin
previous
shown
protect
tegumentar
leishmaniasi
human
obtain
protect
experiment
canin
kalaazar
kennel
fail
detect
signific
differ
vaccine
placebo
well
design
field
assay
ramiro
et
al
obtain
protect
experiment
infect
l
infantum
dog
immun
plasmid
carri
gene
lack
antigen
l
infantum
follow
buster
recombin
vaccinia
viru
contain
gene
protect
vaccin
anim
untreat
control
disclos
increas
express
lymphocyt
prolif
respons
ratio
decreas
clinic
symptom
number
parasit
target
tissu
express
recent
describ
protect
effect
fucos
mannos
ligand
fml
vaccin
canin
viscer
leishmaniasi
fucos
mannos
contain
glycoproteinenrich
fraction
isol
leishmania
donovani
promastigot
name
fml
ligand
sinc
strongli
inhibit
vitro
infect
murin
macrophag
promastigot
amastigot
l
donovani
fml
antigen
present
surfac
parasit
throughout
life
cycl
potent
immunogen
mice
rabbit
sensit
predict
specif
antigen
serodiagnosi
human
canin
kalaazar
fmlsaponin
formul
alreadi
shown
safe
immunogen
protect
phase
iiia
trial
balbc
parasit
load
reduct
swiss
albino
mice
cb
hamster
brazilian
area
endem
human
dog
viscer
leishmaniasi
recent
phase
iii
trial
efficaci
use
fmlvaccin
dog
induc
protect
natur
expos
vacine
vaccin
efficaci
respect
protect
induc
fmlquillaja
saponin
quila
vaccin
last
year
vaccin
time
vaccine
show
higher
seroposit
intraderm
reaction
leishmani
dna
parasit
bone
marrow
punctur
salin
control
hand
show
posit
pcr
leishmania
dna
amastigot
bone
marrow
fmlserolog
intraderm
reaction
fmlquila
vaccin
induc
signific
longlast
strong
protect
effect
canin
kalaazar
field
impress
protect
achiev
fmlvaccin
field
phase
iii
assay
introduc
perspect
largescal
use
dog
vaccin
kalaazar
endem
area
howev
phase
iii
assay
vaccin
candid
healthi
fmlseroneg
anim
larger
use
vaccin
area
serolog
control
obligatori
might
involv
vaccin
asymtpomat
seroposit
seroneg
dog
alreadi
infect
leishmania
noteworthi
serolog
window
canin
viscer
leishmaniasi
diagnosi
rang
day
infect
well
establish
assay
case
would
vaccin
infect
dog
look
immunotherapeut
rather
immunoprophylact
potenti
fmlvaccin
consid
also
rel
failur
chemotherapi
canin
viscer
leishmaniasi
neg
impact
epidemiolog
control
diseas
possibl
use
protect
vaccin
immunotherapi
alreadi
infect
dog
highli
encourag
would
broader
commun
accept
control
effort
base
instead
kill
infect
dog
efficaci
immunotherap
treatment
fmlsaponin
vaccin
recent
prove
balbc
mice
infect
l
donovani
show
specif
increas
antibodi
dth
respons
promastigot
lysat
vitro
ganglion
cell
prolif
respons
fmlantigen
decreas
level
serum
concomitantli
impress
specif
declin
liver
parasit
burden
detect
vaccinetr
anim
indic
therapeut
fmlvaccin
potent
effect
modul
murin
infect
investig
initi
studi
potenti
use
fmlvaccin
immunotherapi
aid
treatment
infect
symptomat
asymptomat
dog
canin
viscer
leishmaniasi
five
mongrel
dog
brood
vaccin
rabi
raivac
canin
distemp
type
adenoviru
coronaviru
parainfluenza
parvoviru
leptospira
duramun
cvklci
fort
dodg
anim
health
iw
usa
anim
experiment
infect
iv
rout
amastigot
obtain
l
donovani
infect
hamster
spleen
vaccin
day
infect
mg
fml
mg
quila
saponin
superfo
biosector
quila
purifi
saponin
kvistgaard
denmark
fmlvaccin
regist
patent
inpi
number
march
feder
univers
rio
de
janeiro
brazil
dog
monthli
analyz
follow
paramet
antifml
antibodi
level
total
igg
igg
igg
delay
type
hypersensit
dth
ft
promastigot
lysat
antigen
clinic
sign
lymphocyt
phenotyp
parasit
evalu
bone
marrow
punctur
smear
one
year
infect
surviv
anim
sacrif
anesthesia
thionembut
via
iv
abbott
laboratori
paulo
brazil
presenc
leishmania
amastigot
assess
giemsa
stain
touch
biopsi
skin
spleen
liver
lymphnod
bone
marrow
smear
group
dog
endem
area
sp
brazil
receiv
three
vaccin
dose
mg
fml
mg
saponin
r
seroposit
fml
complet
asymptomat
also
receiv
first
annual
booster
group
heterogen
includ
individu
kalaazar
highest
suscept
breed
one
cocker
four
german
shepherd
three
fila
three
poodl
two
fox
ine
beagl
three
dasch
hound
one
pinscher
three
rottweil
experi
month
anim
monitor
fmlelisa
assay
total
igg
subtyp
intraderm
reaction
l
donovani
freezethaw
promastigot
lysat
lymphocyt
phenotyp
pbmc
bone
marrow
punctur
clinic
survey
fortysix
asymptomat
fmlseroposit
dog
endem
area
includ
studi
untreat
control
dog
sera
test
presenc
total
antil
donovani
antibodi
fmlelisa
assay
use
fmlantigen
gwell
solubil
carbon
buffer
ph
coat
flatbottom
plate
corn
cat
number
highli
absorb
total
antibodi
detect
use
peroxidaselabel
proteina
kirkegaard
perri
laboratori
gaithersburg
md
dilut
block
buffer
cutoff
fmlelisa
assay
determin
youden
test
calcul
ab
mean
averag
absorb
valu
normal
healthi
serum
plu
two
standard
deviat
furthermor
goat
antidog
heavi
chain
specif
bethyl
laboratori
inc
montgomeri
tx
usa
conjug
horseradishperoxidas
use
igg
subtyp
determin
sera
titrat
twofold
dilut
previous
describ
absorb
valu
compar
use
dilut
individu
serum
sampl
result
express
mean
valu
triplic
determin
inject
dog
intraderm
inner
aspect
right
hind
leg
ml
l
donovani
freezethaw
antigen
contain
g
protein
nacl
steril
salin
solut
stationari
phase
promastigotesml
left
hind
leg
receiv
ml
salin
measur
increas
intraderm
reaction
perform
h
antigen
inject
indur
area
mark
time
valu
salin
control
subtract
reaction
due
leishmania
antigen
reaction
show
diamet
mm
consid
posit
pbmc
obtain
ml
cephal
vein
blood
collect
edtatub
dilut
fac
tm
lyse
solut
becton
dickinson
usa
cell
homogen
incub
min
room
temperatur
centrifug
threetim
fc
ad
pb
well
round
bottom
immunopl
plate
l
one
follow
monoclon
antibodi
dilut
fac
dil
serotec
oxford
uk
l
antirat
serum
fc
supplement
fac
dil
pb
fac
dil
antirat
fitcconjug
use
neg
control
furthermor
l
purifi
pbmc
ad
well
triplic
incub
min
room
temperatur
incub
l
pb
ad
well
plate
centrifug
g
min
room
temperatur
cell
homogen
label
l
fitclabel
igg
sheep
antirat
policlon
antibodi
dilut
fac
dil
assay
antibodi
time
l
fitclabel
mous
monoclon
antibodi
immunotech
co
marseil
franc
use
direct
immunofluoresc
procedur
immunopl
incub
room
temperatur
min
wash
pb
centrifug
cell
final
fix
fac
fix
solut
gl
paraformaldehyd
gl
sodium
cacodyl
gl
sodium
chlorid
ph
transfer
microtub
rel
immunofluoresc
measur
becton
dickinson
fac
calibur
apparatu
becton
dickinson
assay
includ
intern
control
nonspecif
bind
fitcconjug
sheep
antirat
igg
antibodi
also
analyz
pbmc
healthi
leishmaniaseroneg
dog
brazilian
kalaazar
endem
area
belo
horizont
includ
normal
control
test
signific
differ
group
use
confid
interv
averag
mean
averag
continu
variabl
compar
standard
ttest
proport
compar
test
work
aim
investig
efficaci
fmlsaponin
vaccin
immunotherapi
dog
viscer
leishmaniasi
antifml
serolog
respons
experiment
infect
dog
submit
immunotherapi
fmlquila
vaccin
dog
repres
fig
ad
igg
antibodi
start
increas
day
infect
fig
anim
show
respons
cutoff
day
mild
kalaazar
symptom
appear
tabl
rapid
antifml
igg
burst
note
first
vaccin
dose
day
reach
plateau
third
dose
day
maintain
whole
experi
hand
antifml
igg
subtyp
respons
evid
onset
vaccin
schedul
reach
higher
level
fig
c
dog
olygosymptomat
becam
asymptomat
complet
vaccin
tabl
maintain
potent
intraderm
reaction
disclos
protect
respons
achiev
fmlquila
vaccin
heavili
infect
anim
fig
despit
result
dog
suddenli
die
asymptomat
day
infect
dog
number
although
polysymptomat
tabl
surviv
resist
end
experi
maintain
posit
although
minor
idr
fig
idr
reaction
l
donovani
promastigot
lysat
neg
limit
posit
dog
polysymptomat
tabl
develop
rapid
increas
fig
die
kalaazar
day
infect
tabl
analysi
evolut
clinic
symptom
show
protect
dog
becam
asymptomat
month
complet
vaccin
tabl
leishmania
amastigot
absent
bone
marrow
smear
anim
day
immunotherapi
infect
skin
spleen
liver
lymphnod
bone
marrow
touch
biopsi
sacrific
result
indic
protect
viscer
leishmaniasi
achiev
infect
dog
pbmc
flow
cytometri
analysi
fmlquilatr
dog
perform
day
infect
time
dog
dead
dog
polsymptomat
dog
asymtpomat
dog
cure
skin
lesion
anim
show
close
relat
valu
lymphocyt
marker
tabl
low
valu
detect
dog
probabl
artifact
although
averag
valu
lie
outsid
respect
healthi
dog
confid
interv
still
close
normal
valu
percent
valu
remain
within
rang
normal
compar
normal
uninfect
dog
endem
area
noteworthi
percent
significantli
increas
vaccin
dog
percentag
remain
slight
confid
interv
normal
dog
tabl
potenti
immunotherap
effect
fmlsaponin
r
vaccin
investig
group
l
chagasi
natur
infect
dog
endem
area
receiv
three
vaccin
dose
seroposit
fml
complet
asymptomat
igg
antifml
absorb
oscil
begin
experi
cutoff
valu
increas
vaccin
schedul
reach
maximum
day
maintain
plateau
month
fig
level
high
rel
stabl
whole
period
fig
antibodi
hand
show
lower
level
begin
significantli
increas
toward
end
first
year
experi
first
annual
vaccin
burst
reach
maxim
valu
month
fig
dth
respons
posit
anim
whole
experi
fig
signific
variat
time
detect
either
proport
dth
posit
reaction
p
size
skin
test
p
month
parasit
present
dog
bone
marrow
smear
pbmc
flow
cytometri
analysi
perform
tabl
mean
averag
popul
close
level
normal
control
averag
fall
within
confid
interv
normal
dog
dog
show
declin
level
howev
asymptomat
time
evalu
detect
fmlquilatr
dog
fmlsaponin
r
vaccine
show
well
increas
level
lymphocyt
tabl
whole
period
dog
remain
asymptomat
mild
kalaazar
symptom
detect
two
dog
fig
first
one
cocker
show
lymphnod
swell
stomatit
fever
month
treat
cure
allopurinol
second
one
german
shepherd
show
poplit
lymphnod
enlarg
spontan
regress
month
parasit
found
smear
obtain
lymphnod
twentytwo
month
complet
vaccin
therefor
dog
remain
asymptomat
healthi
parasit
free
indic
fmlsaponin
r
formul
effect
induc
protect
viscer
leishmaniasi
asymptomat
infect
dog
control
group
monitor
dog
seroposit
fml
asymptomat
remain
field
receiv
treatment
antifml
igg
antibodi
level
control
group
differ
vaccinetr
group
day
p
fig
also
differ
detect
initi
valu
vaccin
untreat
control
p
absorb
valu
day
lower
untreat
control
p
strike
differ
surviv
rate
vaccin
untreat
anim
detect
confirm
protect
potenti
fmlvaccin
fig
month
anim
symptomat
end
month
dead
kalaazar
record
among
untreat
control
dog
valu
account
dog
positiv
immunofluoresc
assay
show
characterist
symptomatolog
either
spontan
die
sacrif
control
program
number
kalaazar
case
could
underestim
sinc
untreat
control
lost
due
patholog
proprietari
migrat
lost
die
undetermin
reason
n
dog
remain
aliv
asymptomat
month
day
absorb
valu
fig
e
correspond
survivor
hand
kalaazar
obit
detect
dog
becam
symptomat
among
fmlvaccinetr
dog
month
fig
disclos
protect
effect
immunotherapi
treatment
sinc
effect
chemotherapi
treatment
canin
viscer
leishmaniasi
avail
infect
dog
remain
field
constitut
parasit
reservoir
human
infect
effect
immunotherapi
treatment
anim
would
repres
possibl
welcom
altern
massiv
sacrific
seroposit
anim
major
result
obtain
studi
delay
clinic
manifest
diseas
absolut
reduct
death
infect
dog
viscer
leishmaniasi
submit
immunotherapi
fmlvaccin
second
import
find
epidemiolog
impact
indic
immunotherapytr
dog
remain
healthi
probabl
noninfecti
sandfli
disclos
normal
lymphocyt
subtyp
composit
inde
anim
maintain
normal
level
lymphocyt
canin
viscer
leishmaniasi
type
decreas
specif
declin
associ
increas
infect
sandfli
averag
percent
valu
lymphocyt
natur
infect
dog
viscer
leishmaniasi
level
achiev
l
infantum
vaccin
immunochemotherapytr
dog
fmlquila
vaccinetr
anim
show
averag
fmlsaponin
r
strictli
includ
confid
interv
normal
healthi
dog
also
l
infantum
vaccinetr
anim
show
decreas
lymphocyt
count
fmlquila
fmlsaponin
r
vaccin
induc
signific
increas
lymphocyt
subset
normal
rang
percent
increas
higher
fmlquila
vaccin
fmlsaponin
r
vaccin
differ
might
due
differ
composit
two
mixtur
saponin
differ
time
evalu
inde
fac
analysi
fmlquila
group
perform
month
complet
vaccin
data
fmlsaponin
r
anim
correspond
month
annual
vaccin
burst
cytotox
cell
increas
clear
effect
subsequ
saponin
treatment
saponin
glycid
moieti
link
carbon
triterpen
nucleu
carbohydr
moieti
associ
normoterpen
respons
ctl
respons
immunotherapi
experi
fmlquila
vaccin
lack
adequ
control
infect
vaccinetr
anim
igg
antibodi
clinic
sign
idr
result
howev
indic
infect
success
achiev
five
dog
experiment
infect
l
donovani
igg
antibodi
level
cutoff
day
infect
seroconvers
canin
viscer
leishmaniasi
occur
usual
day
experiment
infect
dog
olygosymptomat
show
high
sustain
idr
sinc
day
infect
expect
earli
infect
viscer
leishmaniasi
infect
dog
develop
strong
transitori
idr
respons
leishmani
antigen
day
infect
follow
suppress
idr
advanc
diseas
parasit
load
use
experi
amastigot
iv
high
inde
order
develop
quick
strong
infect
anim
amastigot
howev
absent
bone
marrow
punctur
day
infect
heavi
inoculum
confirm
low
sensit
direct
parasitologyc
method
earli
infect
previou
studi
amastigot
evid
bone
marrow
smear
near
dead
kalaazar
day
infect
differ
suscept
viscer
leishmaniasi
alreadi
describ
dog
macrophag
surfac
nramp
protein
respons
murin
resist
viscer
leishmaniasi
tuberculosi
salmonellosi
show
mutat
viscer
leishmaniasi
suscept
dog
mechan
inherit
genet
marker
yet
defin
previou
work
disclos
evid
familiar
compon
suscept
canin
viscer
leishmaniasi
mongrel
dog
belong
brood
highli
suscept
l
donovani
infect
develop
fatal
diseas
dog
belong
famili
resist
disclos
asymptomat
oligosymptomat
infect
obit
reason
investig
use
anim
brood
aim
reduc
genet
background
variabl
therefor
absenc
diseas
experiment
infect
dog
would
relat
protect
effect
fmlquila
vaccin
rather
individu
genet
determin
resist
viscer
leishmaniasi
fmlquila
vaccin
show
efficaci
immunotherapi
symptomat
experimentallyinfect
dog
maintain
strong
posit
idr
leishmani
antigen
show
normal
lymphocyt
phenotyp
proport
parasit
bone
marrow
target
organ
result
indic
fmlquila
vaccin
might
capabl
induc
protect
statu
healthi
prophylact
vaccin
dog
also
infect
symptomat
dog
submit
immunotherapi
would
remain
noninfecti
agreement
result
immunotherapi
first
gener
leishmania
amazonensi
vaccin
leishvacin
led
high
cure
ratio
human
tegumentar
leishmaniasi
patient
dr
mayrink
person
commun
protect
respons
canin
viscer
leishmaniasi
obtain
fmlvaccin
treatment
higher
report
guarga
et
al
use
first
gener
l
infantum
lysat
vaccin
plu
glucantim
treatment
protect
achiev
treatment
evid
gener
clinic
improv
anim
signific
reduct
infect
rate
sandfli
vector
fed
dog
increas
proport
cell
lymphocyt
especi
cell
howev
lymphnod
aspir
remain
posit
studi
show
immunochemotherapi
induc
posit
chang
immun
respons
reduc
infecti
dog
reservoir
work
also
first
gener
l
braziliensi
vaccin
leishvacin
plu
bcg
combin
three
seri
glucantim
treatment
mayrink
et
al
achiev
protect
canin
viscer
leishmaniasi
five
dog
remain
asymptomat
gain
weight
show
parasit
bone
marrow
skin
biopsi
year
observ
protect
achiev
immunotherapytr
dog
endem
area
evid
number
survivor
inde
dead
kalaazar
record
among
untreat
control
dog
obit
detect
among
vaccine
predomin
subtyp
immunoglobulin
g
dog
might
indic
well
protect
respons
recent
describ
presenc
higher
absorb
l
chagasi
infect
dog
subtyp
predomin
preimmun
sera
fmlvaccin
anim
present
investig
detect
similar
level
immunotherapi
fmltreat
dog
probabl
due
fact
vaccin
began
onset
diseas
develop
antibodi
inde
level
predomin
dog
protect
vaccin
suppress
idr
develop
sever
clinic
kalaazar
die
seem
predomin
character
dog
vaccin
prophylact
similar
level
would
correl
protect
statu
infect
dog
maintain
immunotherapi
fmlquila
vaccin
group
vaccin
fmlsaponin
r
level
high
rel
stabl
whole
period
antibodi
significantli
increas
toward
end
first
year
experi
conclus
predomin
respons
equival
respons
indic
protect
diseas
activ
regard
untreat
control
n
abl
analyz
five
survivor
anim
end
assay
differ
group
develop
sever
viscer
leishmaniasi
die
reduc
group
anim
asymptomat
oligosymptomat
month
show
higher
respons
disclos
possibl
natur
protect
respons
viscer
leishmaniasi
recent
infect
consid
present
epidemiolog
control
campaign
remov
infect
dog
sacrific
chemotherapi
treatment
shown
complet
satisfactori
result
fmlsaponin
vaccin
might
repres
new
tool
use
aid
control
canin
viscer
leishmaniasi
field
